Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon-lambda 3 induction in chronic hepatitis B patients.

Machiko UmemuraKoji Ogawa Kenichi MorikawaAkinori KuboYoshimasa TokuchiRen YamadaTakashi KitagatayaTaku ShigesawaTomoe ShimazakiMegumi KimuraKazuharu SuzukiAkihisa NakamuraMasatsugu OharaNaoki KawagishiTakaaki IzumiMasato NakaiTakuya ShoGoki SudaMitsuteru NatsuizakaKota OnoKazumoto MurataMasaya SugiyamaMasashi MizokamiNaoya Sakamoto

Published in: Hepatology research : the official journal of the Japan Society of Hepatology (2022)

Nucleotide analog (ADV/TDF) treatment reduced HBsAg levels greater compared with nucleoside analog (ETV) in parallel with IFN-λ3 induction.

Keyphrases

hepatitis b virus
end stage renal disease
ejection fraction
dendritic cells
newly diagnosed
chronic kidney disease
acute lymphoblastic leukemia
immune response
prognostic factors
peritoneal dialysis
patient reported
replacement therapy
molecular dynamics simulations